## Phylogeny
Hematopoietic cell kinase (HCK) is classified within the Tyrosine Kinase (TK) group of the eukaryotic protein kinase (ePK) superfamily (manning2002evolutionofprotein pages 1-2, sicheri1997structuresofsrcfamily pages 5-6). Within the TK group, HCK is a member of the Src family of non-receptor tyrosine kinases (alvarado2010crystalstructureof pages 7-8, penedumitrescu2008aninhibitorresistantmutant pages 7-8). The Src kinase family in humans consists of nine members which are subdivided into ubiquitously expressed kinases (SRC, YES, FYN) and those with expression restricted to hematopoietic or specific lineages, which includes HCK, LCK, FGR, BLK, LYN, and YRK (poh2015hematopoieticcellkinase pages 1-3, roversi2017hematopoieticcellkinase pages 1-6). The TK and TKL families represent metazoan-specific expansions within the kinome (manning2002evolutionofprotein pages 1-2). Phylogenetic classification based on kinase domain sequence similarity places HCK within the Src family, which is part of the larger TK group (yaronbarir2024theintrinsicsubstrate pages 16-16, manning2002theproteinkinase pages 2-3).



## Reaction Catalyzed
HCK catalyzes the transfer of a γ-phosphate group from ATP to the hydroxyl group of a tyrosine residue on a protein substrate (alvarado2010crystalstructureof pages 7-8, guiet2008hematopoieticcellkinase pages 16-16, tintori2013identificationofhck pages 1-3). This reaction is characterized as ATP-dependent tyrosine phosphorylation (alvarado2010crystalstructureof pages 1-2, banavali2007anatomyofa pages 1-2).



## Cofactor Requirements
The kinase activity of HCK requires ATP as the phosphoryl donor cofactor (alvarado2010crystalstructureof pages 7-8, poh2015hematopoieticcellkinase pages 1-3, penedumitrescu2008aninhibitorresistantmutant pages 7-8). The catalytic reaction also requires a divalent metal ion; ATP bound to magnesium ions (ATP-2Mg²⁺) is an essential cofactor (banavali2007anatomyofa pages 1-2, alvarado2010crystalstructureof pages 1-2). In vitro, HCK has been reported to prefer Mn²⁺ ions over Mg²⁺ as cofactors (unknownauthors2008investigationofthe pages 71-75).



## Substrate Specificity
HCK's optimal substrate specificity motif is defined by preferred amino acids at positions relative to the phosphorylated tyrosine (position 0) (yaronbarir2024theintrinsicsubstrate pages 16-16). At position P-3, HCK prefers either histidine (H) or arginine (R) (yaronbarir2024theintrinsicsubstrate pages 16-16). At position P-1, the preferred amino acid is lysine (K) (yaronbarir2024theintrinsicsubstrate pages 16-16). At position P+1, HCK shows a preference for glutamine (Q), and at position P+3, the preferred amino acid is asparagine (N) (yaronbarir2024theintrinsicsubstrate pages 16-16).



## Structure
HCK possesses the conserved domain architecture of Src family kinases (SFKs), comprising an N-terminal domain, followed by Src Homology 3 (SH3), SH2, and SH1 (catalytic kinase) domains, and a C-terminal regulatory tail (poh2015hematopoieticcellkinase pages 1-3, sicheri1997structuresofsrcfamily pages 1-2). The SH3 domain binds to proline-rich sequences, while the SH2 domain recognizes phosphotyrosine-containing motifs (unknownauthors2008investigationofthe pages 71-75, poh2015hematopoieticcellkinase pages 1-3). The catalytic domain is bilobal, with a smaller N-terminal lobe containing a dynamic αC-helix and a larger C-terminal lobe; the active site is located between them (selzer2024cocrystallizationofthe pages 1-2, sicheri1997structuresofsrcfamily pages 2-3). Experimentally determined 3D structures for human HCK are available in the Protein Data Bank, including NMR structures of the SH3 domain (PDB IDs 4hck, 5hck), and crystal structures of various constructs: the SH3-SH2 linker region (3NHN), near full-length kinase (1QCF), inhibitor-bound conformations (4LUE), and the isolated kinase domain (5ZJ6) (horita1998solutionstructureof pages 9-10, alvarado2010crystalstructureof pages 1-2, alvarado2010crystalstructureof pages 3-4, selzer2024cocrystallizationofthe pages 2-3). A predicted structure for human HCK (UniProt P08631) is also available from the AlphaFold Protein Structure Database (horita1998solutionstructureof pages 9-10). Key catalytic features include the activation loop with autophosphorylation site Tyr416 (Src numbering) and a conserved DFG motif, and the αC-helix (selzer2024cocrystallizationofthe pages 1-2). A critical ion pair between Lys295 and Glu310 in the αC-helix is essential for ATP positioning and catalysis (sicheri1997structuresofsrcfamily pages 5-6).



## Regulation
The activity of HCK is principally regulated by phosphorylation and intramolecular interactions (poh2015hematopoieticcellkinase pages 1-3). In its inactive state, HCK is maintained in an autoinhibited conformation through the phosphorylation of a C-terminal tyrosine residue (Tyr522, homologous to Tyr527 in c-Src) by kinases such as C-terminal Src kinase (CSK) or CHK (penedumitrescu2008aninhibitorresistantmutant pages 2-4, poh2015hematopoieticcellkinase pages 1-3, selzer2024cocrystallizationofthe pages 8-8). This phosphotyrosine binds intramolecularly to the HCK SH2 domain, while the SH3 domain binds to the SH2-kinase linker, stabilizing the closed, repressed state (sicheri1997structuresofsrcfamily pages 2-3, dorman2019discoveryofnonpeptide pages 1-2). Activation is triggered by the dephosphorylation of this inhibitory C-terminal tyrosine by phosphatases such as CD45, PTPα, TCPTP, or receptor tyrosine phosphatase T (poh2015hematopoieticcellkinase pages 1-3, poh2015hematopoieticcellkinase pages 4-5, carvalho2024comprehensiveanalysisof pages 9-10). This releases the intramolecular constraints and allows for the subsequent trans-autophosphorylation of a tyrosine residue in the activation loop (Tyr410 in human p61HCK, also referred to as Tyr411 or Tyr416), which is required for maximal kinase activity (roversi2017hematopoieticcellkinase pages 1-6, selzer2024cocrystallizationofthe pages 8-8). The engagement of the SH3 and SH2 domains with extracellular signals also contributes to kinase activation, with structural evidence supporting an SH3-dominant activation mechanism (alvarado2010crystalstructureof pages 7-8).



## Function
HCK is a proto-oncogene predominantly expressed in hematopoietic cells of the myeloid (e.g., macrophages, neutrophils) and B-lymphocyte lineages (poh2015hematopoieticcellkinase pages 1-3, carvalho2024comprehensiveanalysisof pages 1-2). It exists as two isoforms, p59HCK and p61HCK, generated by alternative translation initiation (poh2015hematopoieticcellkinase pages 1-3). HCK acts as a signal transducer downstream of various cell surface receptors, including cytokine receptors (IL-2, IL-6, GM-CSF, EpoR), immunoreceptors (TLR4, FCGRs), and integrins (poh2015hematopoieticcellkinase pages 1-3, roversi2017hematopoieticcellkinase pages 1-6). Upstream activators also include mutated MYD88 (yang2016hckisa pages 16-17). Key downstream signaling pathways activated by HCK include PI3K/AKT, MAPK/ERK, and STAT3/STAT5 (roversi2017hematopoieticcellkinase pages 1-6, poh2015hematopoieticcellkinase pages 4-5, carvalho2024comprehensiveanalysisof pages 9-10). HCK interacts with and is activated by oncogenic fusion proteins like BCR/ABL and TEL/ABL (poh2015hematopoieticcellkinase pages 5-7). Other interacting partners include STAT3, RasGAP, paxillin, FLT3, CAMK2G, and HIV-1 Nef (unknownauthors2008investigationofthe pages 71-75, poh2015hematopoieticcellkinase pages 10-11). HCK plays critical roles in innate immunity, regulating macrophage and neutrophil functions such as phagocytosis, degranulation, and migration (carvalho2024comprehensiveanalysisof pages 6-8, poh2015hematopoieticcellkinase pages 5-7). It is also involved in hematopoiesis, particularly the regulation of erythropoiesis and myeloid cell differentiation (roversi2017hematopoieticcellkinase pages 1-6, carvalho2024comprehensiveanalysisof pages 6-8).



## Inhibitors
Multiple small molecule inhibitors target HCK. Broad-spectrum Src family kinase inhibitors that also inhibit HCK include dasatinib, bosutinib, saracatinib, imatinib, SU6656, A-419259, PP1, and PP2 (penedumitrescu2008aninhibitorresistantmutant pages 2-4, poh2015hematopoieticcellkinase pages 10-11, poh2015hematopoieticcellkinase pages 5-7). Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is also a direct HCK inhibitor (yang2016hckisa pages 16-17). More selective or novel pharmacological inhibitors studied in preclinical models include iHCK-37, RK-20449, and KIN-8194, a dual HCK/BTK inhibitor (roversi2017hematopoieticcellkinase pages 1-6, carvalho2024comprehensiveanalysisof pages 6-8).



## Other Comments
Aberrant HCK activation or overexpression is associated with several hematological malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM), and Waldenström’s macroglobulinemia (roversi2017hematopoieticcellkinase pages 1-6, poh2015hematopoieticcellkinase pages 5-7, yang2016hckisa pages 16-17). In AML, elevated HCK expression correlates with unfavorable prognosis (carvalho2024comprehensiveanalysisof pages 6-8). In CML, HCK is implicated in signaling downstream of Bcr-Abl and contributes to imatinib resistance (penedumitrescu2008aninhibitorresistantmutant pages 2-4). HCK is also implicated in solid tumors such as breast, colon, and gastric cancer, often through its role in tumor-associated immune cells (poh2015hematopoieticcellkinase pages 1-3, poh2015hematopoieticcellkinase pages 10-11). Specific disease-linked mutations in HCK are not commonly reported (carvalho2024comprehensiveanalysisof pages 6-8, poh2015hematopoieticcellkinase pages 4-5). However, engineered mutations have revealed key functional sites: the T338M 'gatekeeper' mutation confers resistance to the inhibitor A-419259 via steric hindrance, and the Y527F mutation in the C-terminal tail is constitutively activating and oncogenic (penedumitrescu2008aninhibitorresistantmutant pages 2-4).

References

1. (alvarado2010crystalstructureof pages 7-8): John J. Alvarado, Laurie Betts, Jamie A. Moroco, Thomas E. Smithgall, and Joanne I. Yeh. Crystal structure of the src family kinase hck sh3-sh2 linker regulatory region supports an sh3-dominant activation mechanism. Journal of Biological Chemistry, 285:35455-35461, Nov 2010. URL: https://doi.org/10.1074/jbc.m110.145102, doi:10.1074/jbc.m110.145102. This article has 43 citations and is from a domain leading peer-reviewed journal.

2. (carvalho2024comprehensiveanalysisof pages 6-8): Maria Fernanda Lopes Carvalho, Bruna Oliveira de Almeida, Maura Lima Pereira Bueno, Hugo Passos Vicari, Keli Lima, Eduardo Magalhães Rego, Fernanda Marconi Roversi, and João Agostinho Machado-Neto. Comprehensive analysis of the hck gene in myeloid neoplasms: insights into biological functions, prognosis, and response to antineoplastic agents. Hematology, Transfusion and Cell Therapy, 46:273-282, Jul 2024. URL: https://doi.org/10.1016/j.htct.2023.11.007, doi:10.1016/j.htct.2023.11.007. This article has 3 citations.

3. (carvalho2024comprehensiveanalysisof pages 9-10): Maria Fernanda Lopes Carvalho, Bruna Oliveira de Almeida, Maura Lima Pereira Bueno, Hugo Passos Vicari, Keli Lima, Eduardo Magalhães Rego, Fernanda Marconi Roversi, and João Agostinho Machado-Neto. Comprehensive analysis of the hck gene in myeloid neoplasms: insights into biological functions, prognosis, and response to antineoplastic agents. Hematology, Transfusion and Cell Therapy, 46:273-282, Jul 2024. URL: https://doi.org/10.1016/j.htct.2023.11.007, doi:10.1016/j.htct.2023.11.007. This article has 3 citations.

4. (horita1998solutionstructureof pages 9-10): David A. Horita, Donna M. Baldisseri, Weixing Zhang, Amanda S. Altieri, Thomas E. Smithgall, William H. Gmeiner, and R.Andrew Byrd. Solution structure of the human hck sh3 domain and identification of its ligand binding site. Journal of molecular biology, 278 1:253-65, Apr 1998. URL: https://doi.org/10.1006/jmbi.1998.1690, doi:10.1006/jmbi.1998.1690. This article has 42 citations and is from a domain leading peer-reviewed journal.

5. (penedumitrescu2008aninhibitorresistantmutant pages 2-4): T Pene-Dumitrescu, L F Peterson, N J Donato, and T E Smithgall. An inhibitor-resistant mutant of hck protects cml cells against the antiproliferative and apoptotic effects of the broad-spectrum src family kinase inhibitor a-419259. Oncogene, 27:7055-7069, Nov 2008. URL: https://doi.org/10.1038/onc.2008.330, doi:10.1038/onc.2008.330. This article has 52 citations and is from a domain leading peer-reviewed journal.

6. (poh2015hematopoieticcellkinase pages 1-3): Ashleigh R. Poh, Robert J.J. O’Donoghue, and Matthias Ernst. Hematopoietic cell kinase (hck) as a therapeutic target in immune and cancer cells. Oncotarget, 6:15752-15771, Jun 2015. URL: https://doi.org/10.18632/oncotarget.4199, doi:10.18632/oncotarget.4199. This article has 132 citations and is from a poor quality or predatory journal.

7. (poh2015hematopoieticcellkinase pages 10-11): Ashleigh R. Poh, Robert J.J. O’Donoghue, and Matthias Ernst. Hematopoietic cell kinase (hck) as a therapeutic target in immune and cancer cells. Oncotarget, 6:15752-15771, Jun 2015. URL: https://doi.org/10.18632/oncotarget.4199, doi:10.18632/oncotarget.4199. This article has 132 citations and is from a poor quality or predatory journal.

8. (poh2015hematopoieticcellkinase pages 4-5): Ashleigh R. Poh, Robert J.J. O’Donoghue, and Matthias Ernst. Hematopoietic cell kinase (hck) as a therapeutic target in immune and cancer cells. Oncotarget, 6:15752-15771, Jun 2015. URL: https://doi.org/10.18632/oncotarget.4199, doi:10.18632/oncotarget.4199. This article has 132 citations and is from a poor quality or predatory journal.

9. (poh2015hematopoieticcellkinase pages 5-7): Ashleigh R. Poh, Robert J.J. O’Donoghue, and Matthias Ernst. Hematopoietic cell kinase (hck) as a therapeutic target in immune and cancer cells. Oncotarget, 6:15752-15771, Jun 2015. URL: https://doi.org/10.18632/oncotarget.4199, doi:10.18632/oncotarget.4199. This article has 132 citations and is from a poor quality or predatory journal.

10. (roversi2017hematopoieticcellkinase pages 1-6): Fernanda Marconi Roversi, Fernando Vieira Pericole, João Agostinho Machado-Neto, Adriana da Silva Santos Duarte, Ana Leda Longhini, Flávia Adolfo Corrocher, Bruna Palodetto, Karla Priscila Ferro, Renata Giardini Rosa, Mariana Ozello Baratti, Sergio Verjovski-Almeida, Fabiola Traina, Alessio Molinari, Maurizio Botta, and Sara Teresinha Olalla Saad. Hematopoietic cell kinase (hck) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/pi3k pathway and regulation of erythropoiesis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1863:450-461, Feb 2017. URL: https://doi.org/10.1016/j.bbadis.2016.11.013, doi:10.1016/j.bbadis.2016.11.013. This article has 35 citations.

11. (selzer2024cocrystallizationofthe pages 2-3): Ari M. Selzer, John J. Alvarado, and Thomas E. Smithgall. Cocrystallization of the src-family kinase hck with the atp-site inhibitor a-419259 stabilizes an extended activation loop conformation. Biochemistry, 63:2594-2601, Sep 2024. URL: https://doi.org/10.1021/acs.biochem.4c00323, doi:10.1021/acs.biochem.4c00323. This article has 3 citations and is from a peer-reviewed journal.

12. (sicheri1997structuresofsrcfamily pages 5-6): Frank Sicheri and John Kuriyan. Structures of src-family tyrosine kinases. Current Opinion in Structural Biology, 7:777-785, Dec 1997. URL: https://doi.org/10.1016/s0959-440x(97)80146-7, doi:10.1016/s0959-440x(97)80146-7. This article has 525 citations and is from a peer-reviewed journal.

13. (yang2016hckisa pages 16-17): Guang Yang, Sara J. Buhrlage, Li Tan, Xia Liu, Jie Chen, Lian Xu, Nicholas Tsakmaklis, Jiaji G. Chen, Christopher J. Patterson, Jennifer R. Brown, Jorge J. Castillo, Wei Zhang, Xiaofeng Zhang, Shuai Liu, Philip Cohen, Zachary R. Hunter, Nathanael Gray, and Steven P. Treon. Hck is a survival determinant transactivated by mutated myd88, and a direct target of ibrutinib. Blood, 127:3237-3252, Jun 2016. URL: https://doi.org/10.1182/blood-2016-01-695098, doi:10.1182/blood-2016-01-695098. This article has 127 citations and is from a highest quality peer-reviewed journal.

14. (yaronbarir2024theintrinsicsubstrate pages 16-16): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 59 citations and is from a highest quality peer-reviewed journal.

15. (alvarado2010crystalstructureof pages 1-2): John J. Alvarado, Laurie Betts, Jamie A. Moroco, Thomas E. Smithgall, and Joanne I. Yeh. Crystal structure of the src family kinase hck sh3-sh2 linker regulatory region supports an sh3-dominant activation mechanism. Journal of Biological Chemistry, 285:35455-35461, Nov 2010. URL: https://doi.org/10.1074/jbc.m110.145102, doi:10.1074/jbc.m110.145102. This article has 43 citations and is from a domain leading peer-reviewed journal.

16. (alvarado2010crystalstructureof pages 3-4): John J. Alvarado, Laurie Betts, Jamie A. Moroco, Thomas E. Smithgall, and Joanne I. Yeh. Crystal structure of the src family kinase hck sh3-sh2 linker regulatory region supports an sh3-dominant activation mechanism. Journal of Biological Chemistry, 285:35455-35461, Nov 2010. URL: https://doi.org/10.1074/jbc.m110.145102, doi:10.1074/jbc.m110.145102. This article has 43 citations and is from a domain leading peer-reviewed journal.

17. (banavali2007anatomyofa pages 1-2): Nilesh K. Banavali and Benoît Roux. Anatomy of a structural pathway for activation of the catalytic domain of src kinase hck. Proteins: Structure, Jun 2007. URL: https://doi.org/10.1002/prot.21334, doi:10.1002/prot.21334. This article has 55 citations.

18. (carvalho2024comprehensiveanalysisof pages 1-2): Maria Fernanda Lopes Carvalho, Bruna Oliveira de Almeida, Maura Lima Pereira Bueno, Hugo Passos Vicari, Keli Lima, Eduardo Magalhães Rego, Fernanda Marconi Roversi, and João Agostinho Machado-Neto. Comprehensive analysis of the hck gene in myeloid neoplasms: insights into biological functions, prognosis, and response to antineoplastic agents. Hematology, Transfusion and Cell Therapy, 46:273-282, Jul 2024. URL: https://doi.org/10.1016/j.htct.2023.11.007, doi:10.1016/j.htct.2023.11.007. This article has 3 citations.

19. (dorman2019discoveryofnonpeptide pages 1-2): Heather R. Dorman, David Close, Bentley M. Wingert, Carlos J. Camacho, Paul A. Johnston, and Thomas E. Smithgall. Discovery of non-peptide small molecule allosteric modulators of the src-family kinase, hck. Frontiers in Chemistry, Nov 2019. URL: https://doi.org/10.3389/fchem.2019.00822, doi:10.3389/fchem.2019.00822. This article has 12 citations and is from a peer-reviewed journal.

20. (guiet2008hematopoieticcellkinase pages 16-16): Romain Guiet, Renaud Poincloux, Jerôme Castandet, Louis Marois, Arnaud Labrousse, Véronique Le Cabec, and Isabelle Maridonneau-Parini. Hematopoietic cell kinase (hck) isoforms and phagocyte duties – from signaling and actin reorganization to migration and phagocytosis. European Journal of Cell Biology, 87:527-542, Sep 2008. URL: https://doi.org/10.1016/j.ejcb.2008.03.008, doi:10.1016/j.ejcb.2008.03.008. This article has 86 citations and is from a peer-reviewed journal.

21. (manning2002evolutionofprotein pages 1-2): Gerard Manning, Gregory D Plowman, Tony Hunter, and Sucha Sudarsanam. Evolution of protein kinase signaling from yeast to man. Trends in Biochemical Sciences, 27:514-520, Oct 2002. URL: https://doi.org/10.1016/s0968-0004(02)02179-5, doi:10.1016/s0968-0004(02)02179-5. This article has 1322 citations and is from a domain leading peer-reviewed journal.

22. (manning2002theproteinkinase pages 2-3): G. Manning, D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. The protein kinase complement of the human genome. Science, 298:1912-1934, Dec 2002. URL: https://doi.org/10.1126/science.1075762, doi:10.1126/science.1075762. This article has 10728 citations and is from a highest quality peer-reviewed journal.

23. (penedumitrescu2008aninhibitorresistantmutant pages 7-8): T Pene-Dumitrescu, L F Peterson, N J Donato, and T E Smithgall. An inhibitor-resistant mutant of hck protects cml cells against the antiproliferative and apoptotic effects of the broad-spectrum src family kinase inhibitor a-419259. Oncogene, 27:7055-7069, Nov 2008. URL: https://doi.org/10.1038/onc.2008.330, doi:10.1038/onc.2008.330. This article has 52 citations and is from a domain leading peer-reviewed journal.

24. (selzer2024cocrystallizationofthe pages 1-2): Ari M. Selzer, John J. Alvarado, and Thomas E. Smithgall. Cocrystallization of the src-family kinase hck with the atp-site inhibitor a-419259 stabilizes an extended activation loop conformation. Biochemistry, 63:2594-2601, Sep 2024. URL: https://doi.org/10.1021/acs.biochem.4c00323, doi:10.1021/acs.biochem.4c00323. This article has 3 citations and is from a peer-reviewed journal.

25. (selzer2024cocrystallizationofthe pages 8-8): Ari M. Selzer, John J. Alvarado, and Thomas E. Smithgall. Cocrystallization of the src-family kinase hck with the atp-site inhibitor a-419259 stabilizes an extended activation loop conformation. Biochemistry, 63:2594-2601, Sep 2024. URL: https://doi.org/10.1021/acs.biochem.4c00323, doi:10.1021/acs.biochem.4c00323. This article has 3 citations and is from a peer-reviewed journal.

26. (sicheri1997structuresofsrcfamily pages 1-2): Frank Sicheri and John Kuriyan. Structures of src-family tyrosine kinases. Current Opinion in Structural Biology, 7:777-785, Dec 1997. URL: https://doi.org/10.1016/s0959-440x(97)80146-7, doi:10.1016/s0959-440x(97)80146-7. This article has 525 citations and is from a peer-reviewed journal.

27. (sicheri1997structuresofsrcfamily pages 2-3): Frank Sicheri and John Kuriyan. Structures of src-family tyrosine kinases. Current Opinion in Structural Biology, 7:777-785, Dec 1997. URL: https://doi.org/10.1016/s0959-440x(97)80146-7, doi:10.1016/s0959-440x(97)80146-7. This article has 525 citations and is from a peer-reviewed journal.

28. (tintori2013identificationofhck pages 1-3): Cristina Tintori, Ilaria Laurenzana, Francesco La Rocca, Federico Falchi, Fabio Carraro, Alba Ruiz, José A. Esté, Miroslava Kissova, Emmanuele Crespan, Giovanni Maga, Mariangela Biava, Chiara Brullo, Silvia Schenone, and Maurizio Botta. Identification of hck inhibitors as hits for the development of antileukemia and anti‐hiv agents. ChemMedChem, Aug 2013. URL: https://doi.org/10.1002/cmdc.201300204, doi:10.1002/cmdc.201300204. This article has 54 citations and is from a peer-reviewed journal.

29. (unknownauthors2008investigationofthe pages 71-75): Investigation of the role of haematopoietic cell kinase in normal and leukaemic haematopoiesis
